scholarly journals Antibiotic Resistance of Enteric Bacteria in HIV-Infected Patients at the Banka Ad-Lucem Hospital, West Region of Cameroon

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Ornella J. T. Ngalani ◽  
Armelle T. Mbaveng ◽  
Wiliane J. T. Marbou ◽  
Roland Y. Ngai ◽  
Victor Kuete
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
T Lymphocyte ◽  
Enterobacter Aerogenes ◽  
Hiv Positive ◽  
Hiv Patients ◽  
Hs Crp ◽  
Enteric Disorders ◽  
Hiv Seropositive ◽  
Hiv Negative

Human immunodeficiency virus (HIV) infection is a serious problem throughout the world and especially in developing countries. This study was conducted to define the bacterial aetiologies of enteric disorders and their association with CD4+ T-lymphocyte cell count and serum hs-CRP in HIV-seropositive patients coming for consultation at the AD-Lucem Banka Hospital. Stool samples from one-hundred HIV-positive patients with enteric disorders and forty HIV negative patients with enteric disorders were examined for the presence of bacteria by different diagnostic techniques. CD4+ T-lymphocyte count and serum hs-CRP of HIV-positive and HIV-negative patients were examined, respectively, by flux cytometry and the ELISA solid-phase direct sandwich method. Among all the participants, 39 (26.35%) were males and 109 (73.65%) were females. HIV-seropositive mean age (43.79 years) was significantly higher compared to HIV-seronegative (27.13 years) patients (p<0.000). The average values of CD4+ T-cell count (p<0.0001), lymphocytes (p=0.0258), monocytes (p=0.0317), and total WBC count (p=0.0277) were significantly higher in HIV− patients compared to HIV+ patients. Salmonella sp., Escherichia coli, and Klebsiella pneumoniae were more isolated in HIV+ patients 5 (83.33), 18 (75.00), and 37 (71.15) compared to HIV− patients 1 (16.67), 6 (25.00), and 15 (28.85), respectively. Majority of isolates were susceptible to IPM, NOR, and CIP. Klebsiella pneumoniae, the most prevalent isolate, showed resistance to AMC (45.95) in HIV+ patients, whereas in HIV− patients, Enterobacter aerogenes and Shigella sp. showed resistance to AMC (80.00% and 85.71%, respectively) and to CFM (80.00% and 57.14%, respectively). Enterobacter aerogenes (40.00%) and Shigella sp. (14.29) isolates showed multidrug resistance in HIV− patients, whereas Escherichia coli (5.56%) and Klebsiella pneumoniae (2.70%) showed multidrug resistance in HIV+ patients. Understanding the burden of bacteria disease in HIV patients as shown in the present study is important for planning effective control programs for the overall reduction of bacteria diseases in HIV-infected patients.

Антимікробна резистентність провідних збудників інфекцій сечових шляхів у Києві (Україна)

2017 ◽  
Vol 1 (2) ◽  
pp. 48-60
Author(s):  
A.G. Salmanov ◽  
A.V. Rudenko
Keyword(s):  
Escherichia Coli ◽  
Pseudomonas Aeruginosa ◽  
Klebsiella Pneumoniae ◽  
Staphylococcus Epidermidis ◽  
Klebsiella Oxytoca ◽  
Enterobacter Aerogenes ◽  
Enterobacter Cloacae ◽  
Proteus Vulgaris ◽  
Providencia Rettgeri ◽  
E Coli

Мета роботи — вивчити резистентність до антибіотиків бактеріальних збудників інфекцій сечових шляхів (ІСШ), виділених у пацієнтів урологічного стаціонару в м. Києві. Матеріали і методи. Досліджено 1612 штамів бактерій, виділених із сечі хворих з ІСШ (цистит, уретрит, пієлонефрит), госпіталізованих в урологічне відділення ДУ «Інститут урології НАМН України» у м. Києві протягом 2016 р. Серед пацієнтів переважали жінки — 1201 (74,5 %). Вік хворих становив від 17 до 74 років. Для збору даних використано медичну документацію лікарні. Мікробіологічні дослідження виконано у лабораторії мікробіології ДУ «Інститут урології НАМН України». Аналізували результати культурального дослідження зразків сечі, зібраних за наявності клінічних ознак ІСШ. Дослідження клінічного матеріалу та інтерпретацію отриманих результатів проводили загальноприйнятими методами. Вивчено чутливість уропатогенів до 31 антибіотика дискодифузійним методом відповідно до рекомендацій Інституту клінічних та лабораторних стандартів США (Clinical and Laboratory Standards Institute (CLSI)). Результати та обговорення. Аналіз мікробного спектра сечі виявив домінування серед уропатогенів штамів Escherichia coli (32,0 %), Enterococcus faecalis (19,5 %), Klebsiella pneumoniae (10,9 %), Staphylococcus epidermidis (8,9 %), S. haemolyticus (6,5 %) та Pseudomonas aeruginosa (6,4 %). Частка Enterococcus faecium, Enterobacter aerogenes і Streptococcus viridans становила відповідно 2,5, 2,2 і 1,6 %, Enterobacter cloacae, Klebsiella oxytoca, Acinetobacter baumannii, Proteus vulgaris та Providencia rettgeri — менше 1,0 %. У більшості випадків (69,7 %) мікроорганізми виділено у монокультурі, у решті випадків — у мікробних асоціа- ціях. Високу резистентність до тестованих антибіотиків виявили штами E. aerogenes (45,1 %), E. cloacae (45,7 %), E. faecium (40,9 %), E. faecalis (40,7 %), E. coli (39,9 %), P. aeruginosa (34,0 %), K. pneumoniae (28,6 %). Найбільш активними до уропатогенів були іміпенем (E. coli — 87,6 %, P. aeruginosa — 75,7 %, E. cloacae — 67,3 %, E. aerogenes — 72,6 %, K. pneumoniae — 93,2 %), меропенем (E. coli — 89,1 %, P. aeruginosa — 76,7 %, K. pneumoniae — 82,6 %), лефлоцин (E. coli — 74,5 %, ентерококи — 78,7 %, P. aeruginosa — 76,7 %, E. cloacae — 73,9 %, E. aerogenes — 80,4 %, K. pneumoniae — 83,5 %), амоксицилін/клавуланат (ентерококи — 84,6 %), фурагін (ентерококи — 82,6 %), цефоперазон (K. pneumoniae — 89,2 %, P. aeruginosa — 73,8 %), цефтріаксон (K. pneumoniae — 80,1 %). Висновки. Антибіотикорезистентність збудників ІСШ — важлива терапевтична проблема. Найбільшою активністю до уропатогенів характеризуються іміпенем, меропенем, лефлоцин, амоксицилін/ клавуланат, фурагін, цефоперазон, цефтріаксон, які можна розглядати як препарат вибору для призначення стартової терапії ІСШ. Необхідно здійснювати постійний моніторинг за резистентністю до дії антибіотиків. Політику використання антибіотиків у кожному стаціонарі слід визначати залежно від локальних даних щодо резистентності до протимікробних препаратів.

Evaluation of microalbumin, cystatin c, creatinine and uric acid levels in HIV patients in Nnamdi Azikiwe University Teaching Hospital, Nnewi

2021 ◽  
Vol 8 (3) ◽  
pp. 132-142
Author(s):  
Ezeugwunne Ifeoma Priscilla ◽  
Amaifeobu Clement ◽  
Meludu Samuel Chukwuemeka ◽  
Analike Rosemary Adamma ◽  
Nnamdi Johnjude Chinonso ◽  
...  
Keyword(s):  
Uric Acid ◽  
Cystatin C ◽  
Teaching Hospital ◽  
University Teaching ◽  
Hiv Positive ◽  
Hiv Patients ◽  
Voluntary Counseling And Testing ◽  
Group B ◽  
And Control ◽  
Hiv Negative

This study evaluated the microalbumin, cystatin C, creatinine and uric acid levels in HIV patients in Nnamdi Azikiwe University Teaching Hospital, Nnewi (NAUTH). A total of one hundred (100) male and female HIV positive and control participants who were aged between 18 and 60 years attending the voluntary counseling and testing unit (VCT) and antiretroviral therapy unit (ART) of NAUTH were randomly recruited for the study and grouped thus: Group A (HIV positive symptomatic participants on long term ART (HPSPLTART) (n= 25); Group B (HIV positive symptomatic participants on short term ART (HPSPSTART) (n= 25); Group C: Asymptomatic HIV positive participants NOT on ART (AHPPNART) (n=25) and Group D: control (n=25).6mls of blood sample and 10mls of freshly voided urine samples were collected from each of the participants for the evaluation of biochemical parameters using standard laboratory methods. Results showed significantly higher BMI and SBP in HPSPSTART than in control (p=0.04; 0.02). SBP was significantly higher in HPSPLTART than in AHPPNART and Control (p=0.00). DBP was significantly higher in HPSPLTART than in HPSPSTART and control respectively (p=0.00). There were significantly higher plasma creatinine and Cys-C levels in both male HIV positives and male HIV positive participants on ART than in both females respectively (p0.00; 0.02). Also, BMI, creatinine, uric acid and Cystatin C levels were significantly higher in male HIV negative participants than in female HIV negative participants (p=0.00; 0.04; 0.02; 0.01). This study has revealed greater risk for renal disease among the HIV participants studied.

scholarly journals Contaminación con bacterias patógenas de estetoscopios del personal médico en un hospital de nivel III en Lima, Perú

2016 ◽  
Vol 27 (2) ◽  
pp. 83 ◽  
Author(s):  
José Enrique Oliva-Menacho ◽  
Marco Antonio García-Hjarles ◽  
José Arturo Oliva-Candela ◽  
Hugo Saturnino De la Cruz-Roca
Keyword(s):  
Escherichia Coli ◽  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Klebsiella Pneumoniae ◽  
Enterobacter Aerogenes ◽  
Macconkey Agar ◽  
Acinetobacter Spp ◽  
Staphylococcus Spp ◽  
Hospital General

Objetivos: Determinar el grado de contaminación bacteriana con bacterias patógenas de los estetoscopios del personal médico en un hospital general de Lima, Perú. Material y métodos: Estudio de tipo observacional, descriptivo y transversal, realizado en el Hospital Nacional Arzobispo Loayza, entre los meses de enero y juniodel 2013. Se estudiaron 124 muestras de estetoscopios del personal médico en las siguientes áreas: UCI 20; neonatología 13; quemados 3; medicina 52; emergencia 36. Se recolectaron las muestras con hisopos humedecidos, en condiciones estériles (En presencia de un mechero de vidrio para alcohol) y luego fueron introducidos en tuboscon preparado de caldo BHI (Infusión cerebro corazón) para ser incubados por 24 horas a 37°C; se cultivó en Agar sangre, Agar MacConkey, Agar manitol y Agar cetrimidepara su posterior determinación de bacterias patógenas por procedimientos bioquímicos ,luego se identificó la susceptibilidad bacteriana con la técnica de Kirby- Bauer. Resultados: De los 124 estetoscopios estudiados; 114 (91,9%) estuvieron contaminados; se aislaron 123 cepasbacterianas: Staphylococcus spp coagulasa negativa 106(86,1%), Staphylococcus aureus 5(4,0%), Enterobacter aerogenes 4 (3,2%), Acinetobacter spp 2(1,6%), Pseudomonas aeruginosa 4(3,2%), Klebsiella Pneumoniae 1(0,8%) y Escherichia coli 1(0,8%). Conclusiones: El aislamiento de bacterias patógenas sugiere que el estetoscopio debe ser considerado como un vector de la infección nosocomial.

Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 beta-lactamase (LAT-2).

1996 ◽  
Vol 40 (7) ◽  
pp. 1736-1740 ◽  
Author(s):  
M Gazouli ◽  
L S Tzouvelekis ◽  
E Prinarakis ◽  
V Miriagou ◽  
E Tzelepi
Keyword(s):  
Escherichia Coli ◽  
Amino Acids ◽  
Klebsiella Pneumoniae ◽  
Enterobacter Aerogenes ◽  
Citrobacter Freundii ◽  
Beta Lactamase ◽  
Beta Lactamases ◽  
Greek Hospitals ◽  
Group 1

Cefoxitin resistance in Klebsiella pneumoniae from Escherichia coli strains isolated in Greek hospitals was found to be due to the acquisition of similar plasmids coding for group 1 beta-lactamases. The plasmids were not self-transferable but were mobilized by conjugative plasmids. These elements have also been spread to Enterobacter aerogenes. The most common enzyme was a Citrobacter freundii-derived cephalosporinase (LAT-2) which differed from LAT-1 by three amino acids.

Shellac Formulations To Reduce Epiphytic Survival of Coliform Bacteria on Citrus Fruit Postharvest†

2001 ◽  
Vol 64 (11) ◽  
pp. 1756-1760 ◽  
Author(s):  
RAYMOND G. McGUIRE ◽  
ROBERT D. HAGENMAIER
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Limit Of Detection ◽  
Citrus Fruit ◽  
Enterobacter Aerogenes ◽  
Coliform Bacteria ◽  
Undetectable Level ◽  
Neutral Solution ◽  
E Coli ◽  
Epiphytic Survival

Survival of the coliform bacteria Enterobacter aerogenes and Escherichia coli was monitored in a neutral carboxyme-thylcellulose formulation and in shellac formulations with various pH and concentrations of ethanol and the preservative paraben; populations were subsequently measured from the surface of citrus fruit coated with these formulations. Numbers of the two bacteria increased over 24 h from 106 CFU/ml to approximately 108 CFU/ml in the carboxymethylcellulose solution, but over this time numbers remained little changed in the neutral solution of shellac. The Enterobacter was more tolerant of alcohol over a 3-h period; although its numbers in a shellac solution with 10% ethanol dropped from more than 106 CFU/ml to just over 103 CFU/ml, E. coli and a third species, Klebsiella pneumoniae, declined toward the limit of detection (5 CFU/ml) during this time. The addition of morpholine to increase the formulation pH to 9.0 caused numbers of bacteria to plummet to an undetectable level within 30 to 60 min. On Ruby Red grapefruit and Valencia oranges in storage at 13°C numbers of E. aerogenes and E. coli declined over 2 weeks from 105 CFU/cm2 to less than 2.5 × 101, but most of the loss in numbers occurred within 1 day. Numbers remained significantly less on shellacked fruit compared with those applied in the carboxymethylcellulose coating, and a shellac coating prepared from a pH 9 solution was more toxic to these species than one in which 12% ethanol had been added to the neutral formulation. The addition of the preservative paraben in the basic shellac was further inhibitory.

Comparison of VRB and VRB-2 Agars for Recovery of Stressed Coliforms From Stored Acidified Half-and-Half1

1982 ◽  
Vol 45 (7) ◽  
pp. 584-585 ◽  
Author(s):  
C. L. REBER ◽  
R. T. MARSHALL
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Enterobacter Aerogenes ◽  
Coliform Bacteria ◽  
E Coli ◽  
Culture Viability

Half-and-half was acidified with delta-gluconolactone, inoculated with three species of coliform bacteria, stored for 31 days at 5 °C, and examined for numbers of viable coliforms on VRB and VRB-2 agars. Loss of culture viability was logarithmic with recovery of 50 and 10% of initial numbers on days 7 and 30, respectively. Escherichia coli had significantly more recoverable injured cells than did Enterobacter aerogenes or Klebsiella pneumoniae. As time of storage increased, the proportion of injured to noninjured cells also increased. However, the maximal number of injured cells was on the thirteenth day of storage of E. coli-inoculated product. VRB-2 agar averaged 20% higher in productivity than VRB agar.

Therapy Related Leukemia in HIV Patients after Treatment for Non-Hodgkin Lymphoma

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5284-5284
Author(s):  
Jed Katzel ◽  
Sanford Kempin ◽  
David Vesole ◽  
Portia Lagmay-Fuentes ◽  
William Cook ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Flow Cytometry ◽  
Radiation Therapy ◽  
Antiretroviral Therapy ◽  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma ◽  
Hiv Positive ◽  
Secondary Malignancies ◽  
Hiv Patients ◽  
Hiv Negative

Abstract Therapy related secondary malignancies after NHL are well characterized in the HIV negative population. The increased risk of secondary leukemia is most commonly associated with alkylating agents, topoisomerase II inhibitors and radiation therapy. We describe 2 patients with HIV-associated Burkitt’s lymphoma who subsequently developed acute leukemia. Case Report 1: An HIV positive 60 yr old male was diagnosed with Burkitt’s lymphoma five years after beginning antiretroviral therapy. Lymph node flow cytometry demonstrated: CD10+, CD19+, CD20+, KAPPA+. He achieved a complete remission after completing the Vanderbilt regimen (cyclophosphamide, methotrexate, bleomycin, vincristine, and doxorubicin) (McMaster M, et al. J Clin Oncol. 1991:9:941–946). Eight years later, he presented with acute myelomonocytic leukemia (M4) after a myelodysplastic prodrome. Flow cytometry demonstrated CD11c+, CD13+, CD33+, CD34+, CD 64+ and cytogenetics showed 5q(−) and 20q(−). He received induction chemotherapy with arsenic trioxide and low dose cytarabine. He did not achieve a remission, and died 2 months later. Case Report 2: A 45 yr old male presented with severe abdominal pain, and fever. During laparotomy, he was found to have a cecal mass consistent with Burkitt’s lymphoma. A bone marrow biopsy also showed Burkitt’s lymphoma: CD10+, CD19+, CD20+, CD22+, CD 38+, CD45+, CD71+. He was subsequently diagnosed with HIV with a CD4 count of 60/uL. He was treated with CODOX-M (cyclophosphamide, doxorubicin, vincristine, methotrexate, IT cytarabine, IT methotrexate) and IVAC (Ifosfamide, etoposide, cytarabine, IT methotrexate) (Magrath I, et al. J Clin Oncol1996;14:925–934) achieving a CR. He remained on antiretroviral therapy throughout his course. Two years later, he presented with thrombocytopenia. A bone marrow aspirate was consistent with precursor B-cell ALL CD19+, CD34+, CD79a+ and TdT+ distinct from the previous Burkitt’s lymphoma. He was treated with the L20 (Clarkson B, et al. Haematol Blood Transfus1990;33:397–408) protocol achieving a durable CR. He continued his retroviral therapy during his treatment. Conclusions: HIV positive patients have an increased propensity to develop malignancy independent of prior chemotherapy or radiotherapy exposure. In the era of HAART, the survival of HIV positive patients has markedly improved. Although the role of chemotherapy and radiation therapy are well documented as causative agents of neoplasia, the risk of HAART therapy with toxicity of nuclear, cytoplasmic and cell membrane effects potentially inducing malignancies is less well defined. Many of these agents are considered oncogenic in animal models but have not been proven to cause tumors in humans. However, it is conceivable, given the cellular toxicities of antineoplastic and antiretroviral therapy, that in combination they could cause myelodysplasia or further lymphodysplasia. It is too early to know if HIV patients are at a greater risk for development of secondary malignancies as a long-term complication of chemotherapy. However, because recent studies have demonstrated that HIV+ patients on highly active antiretroviral therapy (HAART) have comparable responses to chemotherapy compared to HIV negative patients, we recommend that patients continue HAART while receiving treatment for malignancy. Close surveillance for the appearance of secondary leukemias is warranted.

KPC-2 carbapenemase and DHA-1 AmpC determinants carried on the same plasmid in Enterobacter aerogenes

2014 ◽  
Vol 63 (3) ◽  
pp. 367-370 ◽  
Author(s):  
Shougang Kuai ◽  
Haifeng Shao ◽  
Lihua Huang ◽  
Hao Pei ◽  
Zhonghua Lu ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Clinical Isolate ◽  
Southern Blotting ◽  
Antimicrobial Agents ◽  
Resistance Mechanism ◽  
Enterobacter Aerogenes ◽  
Carbapenem Resistance ◽  
Jiangsu Province ◽  
Republic Of China

This study was conducted to analyse the presence of a plasmid-mediated carbapenem resistance mechanism in a clinical Enterobacter aerogenes isolate from a patient from Jiangsu province, People’s Republic of China. PCR and sequencing confirmed that the isolate harboured Klebsiella pneumoniae carbapenemase (KPC)-2, DHA-1 and TEM-1 β-lactamase genes. Both the KPC-2 and DHA-1 genes were transferred to Escherichia coli C600 by transconjugation, and Southern blotting confirmed that these two genes were located on the same plasmid, which was of approximately 56 kb in size. The Enterobacter aerogenes isolate was resistant to carbapenems and other tested antimicrobial agents. The Escherichia coli transconjugant showed reduced susceptibility but not resistance to carbapenems and other β-lactams, indicating the presence of another, possibly permeability-related, resistance mechanism in the clinical isolate.

scholarly journals Nationwide Study of the Prevalence, Characteristics, and Molecular Epidemiology of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in France

2007 ◽  
Vol 52 (2) ◽  
pp. 786-789 ◽  
Author(s):  
Muriel Galas ◽  
Jean-Winoc Decousser ◽  
Nelly Breton ◽  
Thierry Godard ◽  
Pierre Yves Allouch ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
Molecular Epidemiology ◽  
Molecular Analysis ◽  
Enterobacter Aerogenes ◽  
Nationwide Study ◽  
E Coli ◽  
Extended Spectrum ◽  
Prevalent Species

ABSTRACT Among 10,872 isolates of Enterobacteriaceae from a nationwide study of 88 French hospitals in 2005, 169 (1.7%) expressed an extended-spectrum β-lactamase. The most prevalent species were Escherichia coli (48.5%), Enterobacter aerogenes (23.7%), and Klebsiella pneumoniae (14.8%). Molecular analysis underlined the polyclonal spread of CTX-M-expressing E. coli, primarily isolates of the CTX-M-1 subgroup.

scholarly journals Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Bradley T. Williamson ◽  
Heather A. Leitch
Keyword(s):  
Bone Marrow ◽  
Viral Load ◽  
Antiretroviral Therapy ◽  
Myelodysplastic Syndromes ◽  
Hiv Positive ◽  
Combination Antiretroviral Therapy ◽  
Hiv Viral Load ◽  
Hiv Patients ◽  
Age Of Diagnosis ◽  
Hiv Negative

Introduction. In advanced HIV prior to combination antiretroviral therapy (ART), dysplastic marrow changes occurred and resolved with ART. Few reports of myelodysplastic syndromes (MDS) in well-controlled HIV exist and management is undefined.Methods. Patients with well-controlled HIV and higher risk MDS were identified; characteristics, treatment, and outcomes were reviewed.Results. Of 292 MDS patients since 1996, 1 (0.3%) was HIV-positive. A 56-year-old woman presented with cytopenias. CD4 was 1310 cells/mL and HIV viral load <40 copies/mL. Bone marrow biopsy showed RCMD and karyotype included del(5q) and del(7q); IPSS was intermediate-2 risk. She received azacitidine at 75% dose. Cycle 2, at full dose, was complicated by marrow aplasia and possible AML; she elected palliation. Three additional HIV patients with higher risk MDS, aged 56–64, were identified from the literature. All had deletions involving chromosomes 5 and 7. MDS treatment of 2 was not reported and one received palliation; all died of AML.Conclusion. Four higher risk MDS in well-controlled HIV were below the median age of diagnosis for HIV-negative patients; all had adverse karyotype. This is the first report of an HIV patient receiving MDS treatment with azacitidine. Cytopenias were profound and dosing in HIV patients should be considered with caution.

Sign in / Sign up

Export Citation Format

Share Document